Sowell Financial Services LLC grew its position in Celgene Co. (NASDAQ:CELG) by 84.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,762 shares of the biopharmaceutical company’s stock after acquiring an additional 2,175 shares during the quarter. Sowell Financial Services LLC’s holdings in Celgene were worth $484,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Arcadia Investment Management Corp MI lifted its position in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares during the period. Thompson Davis & CO. Inc. lifted its position in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 43 shares during the period. Robecosam AG bought a new position in shares of Celgene during the 3rd quarter worth approximately $114,000. Capital Bank & Trust Co lifted its position in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 517 shares during the period. Finally, Guidant Wealth Advisors bought a new position in shares of Celgene during the 3rd quarter worth approximately $119,000. Institutional investors own 77.84% of the company’s stock.
Several equities analysts recently commented on the company. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $116.84 target price for the company in a research report on Thursday, January 25th. Mizuho set a $128.00 target price on Celgene and gave the stock a “buy” rating in a research report on Tuesday, December 26th. BTIG Research restated a “hold” rating on shares of Celgene in a research report on Tuesday, January 23rd. BidaskClub upgraded Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, Citigroup restated a “hold” rating on shares of Celgene in a research report on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $129.08.
Shares of Celgene Co. (NASDAQ CELG) opened at $95.78 on Wednesday. Celgene Co. has a twelve month low of $88.32 and a twelve month high of $147.17. The firm has a market capitalization of $72,577.42, a price-to-earnings ratio of 26.75, a P/E/G ratio of 0.68 and a beta of 1.49. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29.
Celgene (NASDAQ:CELG) last released its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The business’s revenue was up 16.9% on a year-over-year basis. During the same period last year, the firm posted $1.61 EPS. equities analysts anticipate that Celgene Co. will post 7.68 earnings per share for the current fiscal year.
Celgene announced that its board has approved a stock buyback plan on Wednesday, February 14th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: “Sowell Financial Services LLC Increases Holdings in Celgene Co. (CELG)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3228735/sowell-financial-services-llc-increases-holdings-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.